Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515866 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT00515866 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 68 participants.
The verdict
NCT00515866, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with gemcitabine chemotherapy for the treatment of pancreatic cancer.
Interventions
- DRUG Gemcitabine
- DRUG KU-0059436 (AZD2281)(PARP inhibitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00515866
The ClinicalTrials.gov registry entry for NCT00515866 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00515866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00515866 about?
NCT00515866 is a clinical study titled "Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer". The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with gemcitabine chemotherapy for the treatment of pancreatic cancer.
What is the current status of trial NCT00515866?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2007-08. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00515866?
The interventions under investigation include: Gemcitabine (DRUG), KU-0059436 (AZD2281)(PARP inhibitor) (DRUG).
Who is sponsoring clinical trial NCT00515866?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.